Implication of the Autologous Immune System in BCR-ABL Transcript Variations in Chronic Myelogenous Leukemia Patients Treated with Imatinib. [electronic resource]
Producer: 20160130Description: 4053-62 p. digitalISSN:- 1538-7445
- Antineoplastic Agents -- pharmacology
- Cell Differentiation
- Clone Cells -- pathology
- Computer Simulation
- Fusion Proteins, bcr-abl -- biosynthesis
- Gene Expression Regulation, Neoplastic -- immunology
- Humans
- Imatinib Mesylate -- pharmacology
- Immunologic Surveillance
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive -- drug therapy
- Models, Biological
- Neoplastic Stem Cells -- immunology
- Protein Kinase Inhibitors -- pharmacology
- RNA, Messenger -- biosynthesis
- RNA, Neoplasm -- biosynthesis
- Remission Induction
- Transcription, Genetic -- immunology
- Treatment Outcome
- Tumor Burden
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
There are no comments on this title.
Log in to your account to post a comment.